Ofloxacin ophthalmic solution

Drug Profile

Ofloxacin ophthalmic solution

Alternative Names: Exocin; Ocuflox; Oflovid; Oflox; Tarivid

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company; Santen Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Corneal ulcer; Infectious conjunctivitis; Ophthalmic infections

Most Recent Events

  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 27 Nov 2000 Dura Pharmaceuticals has been acquired by Elan Corporation
  • 31 Dec 1993 Launched for Conjunctivitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top